During the COVID-19 pandemic, the development of prophylactic vaccines, including those based on new platforms, became highly relevant. One such platform is the creation of vaccines combining DNA and protein components in one construct. For the creation of DNA vaccine, we chose the full-length spike protein (S) of the SARS-CoV-2 virus and used the recombinant receptor-binding domain (RBD) of the S protein produced in CHO-K1 cells as a protein component. The immunogenicity of the developed combined vaccine and its individual components was compared and the contribution of each component to the induction of the immune response was analyzed. The combined DNA/protein vaccine possesses the advantages of both underlying approaches and is capable of inducing both humoral (similar to subunit vaccines) and cellular (similar to DNA vaccines) immunity.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Simões RSQ, Rodríguez-Lázaro D. Classical and next-generation vaccine platforms to SARS-CoV-2: biotechnological strategies and genomic variants. Int. J. Environ. Res. Public Health. 2022;19(4):2392. doi: https://doi.org/10.3390/ijerph19042392
Chavda VP, Pandya R, Apostolopoulos V. DNA vaccines for SARS-CoV-2: toward third-generation vaccination era. Expert Rev. Vaccines. 2021;20(12):1549-1560. doi: https://doi.org/10.1080/14760584.2021.1987223
DeFrancesco L. Whither COVID-19 vaccines? Nat. Biotechnol. 2020;38(10):1132-1145. doi: https://doi.org/10.1038/s41587-020-0697-7
Lagunas-Rangel FA, Chávez-Valencia V. What do we know about the antibody responses to SARS-CoV-2? Immunobiology. 2021;226(2):152054. doi: https://doi.org/10.1016/j.imbio.2021.152054
Sun Z, Wu T, Xie H, Li Y, Zhang J, Su X, Qi H. The role of cellular immunity in the protective efficacy of the SARS-CoV-2 vaccines. Vaccines (Basel). 2022;10(7):1103. doi: https://doi.org/10.3390/vaccines10071103
Borgoyakova MB, Karpenko LI, Rudometov AP, Shanshin DV, Isaeva AA, Nesmeyanova VS, Volkova NV, Belenkaya SV, Murashkin DE, Shcherbakov DN, Volosnikova EA, Starostina EV, Orlova LA, Danilchenko NV, Zaikovskaya AV, Pyankov OV, Ilyichev AA. Immunogenic properties of the DNA construct encoding the receptor-binding domain of the SARS-CoV-2 spike protein. Mol. Biol. 2021;55(6):889-898. doi: https://doi.org/10.1134/S0026893321050046
Merkuleva IA, Shcherbakov DN, Borgoyakova MB, Shanshin DV, Rudometov AP, Karpenko LI, Belenkaya SV, Isaeva AA, Nesmeyanova VS, Kazachinskaia EI, Volosnikova EA, Esina TI, Zaykovskaya AV, Pyankov OV, Borisevich SS, Shelemba AA, Chikaev AN, Ilyichev AA. Comparative Immunogenicity of the Recombinant Receptor-Binding Domain of Protein S SARS-CoV-2 Obtained in Prokaryotic and Mammalian Expression Systems. Vaccines (Basel). 2022;10(1):96. doi: https://doi.org/10.3390/vaccines10010096
Borgoyakova MB, Karpenko LI, Rudometov AP, Volosnikova EA, Merkuleva IA, Starostina EV, Zadorozhny AM, Isaeva AA, Nesmeyanova VS, Shanshin DV, Baranov KO, Volkova NV, Zaitsev BN, Orlova LA, Zaykovskaya AV, Pyankov OV, Danilenko ED, Bazhan SI, Shcherbakov DN, Taranin AV, Ilyichev AA. Self-assembled particles combining SARS-CoV-2 RBD protein and RBD DNA vaccine induce synergistic enhancement of the humoral response in mice. Int. J. Mol. Sci. 2022;23(4):2188. doi: https://doi.org/10.3390/ijms23042188
Karpenko LI, Apartsin EK, Dudko SG, Starostina EV, Kaplina ON, Antonets DV, Volosnikova EA, Zaitsev BN, Bakulina AY, Venyaminova AG, Ilyichev AA, Bazhan SI. Cationic polymers for the delivery of the Ebola DNA vaccine encoding artificial T-cell immunogen. Vaccines (Basel). 2020;8(4):718. doi: https://doi.org/10.3390/vaccines8040718
Karpenko LI, Ilyichev AA, Eroshkin AM, Lebedev LR, Uzhachenko RV, Nekrasova NA, Plyasunova OA, Belavin PA, Seregin SV, Danilyuk NK, Zaitsev BN, Danilenko ED, Masycheva VI, Bazhan SI. Combined virus-like particle-based polyepitope DNA/protein HIV-1 vaccine design, immunogenicity and toxicity studies. Vaccine. 2007;25(21):4312-4323. doi: https://doi.org/10.1016/j.vaccine.2007.02.058
Rosati M, Agarwal M, Hu X, Devasundaram S, Stellas D, Chowdhury B, Bear J, Burns R, Donohue D, Pessaint L, Andersen H, Lewis MG, Terpos E, Dimopoulos MA, Wlodawer A, Mullins JI, Venzon DJ, Pavlakis GN, Felber BK. Control of SARS-CoV-2 infection after Spike DNA or Spike DNA+Protein co-immunization in rhesus macaques. PLoS Pathog. 2021;17(9):e1009701. doi: https://doi.org/10.1371/journal.ppat.1009701
Author information
Authors and Affiliations
Corresponding author
Additional information
Translated from Byulleten’ Eksperimental’noi Biologii i Meditsiny, Vol. 174, No. 8, pp. 212-216, August, 2022
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Borgoyakova, M.B., Karpenko, L.I., Merkulyeva, I.A. et al. Immunogenicity of the DNA/Protein Combined Vaccine against COVID-19. Bull Exp Biol Med 174, 246–249 (2022). https://doi.org/10.1007/s10517-023-05682-9
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10517-023-05682-9